Results 131 to 140 of about 3,390 (181)

The Nuclear Transporter Transportin-3 Functions Under Oxidative Stress. [PDF]

Cells
Barling MAL, Thomas DR, Jans DA, Wagstaff KM.   +3 more
europepmc   +1 more source

Structural basis for the synergistic assembly of the snRNA export complex. [PDF]

Nat Struct Mol Biol
Dubiez E, Garland W, Finderup Brask M, Boeri Erba E, Heick Jensen T, Kadlec J, Cusack S.   +6 more
europepmc   +1 more source

CDK9 interacts with a RanGTP-importin-β complex to regulate erythroid enucleation. [PDF]

J Cell Sci
Newton LM, Lim KYB, Abeid DY, Wölwer CB, Johnson CJ, Russell SM, Hawkins ED, Humbert PO.   +7 more
europepmc   +1 more source

Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer. [PDF]

J Biomed Sci
Guo C, Fan Z, Guo C, Yang Y, Hou H, Sun D.   +5 more
europepmc   +1 more source

Pathologies at the gateway: exploring the link between nucleoporins and inherited diseases. [PDF]

Cell Mol Life Sci
Braun DA, Jühlen R, Krausel V, Antonin W.   +3 more
europepmc   +1 more source

Phosphate-dependent nuclear export via a non-classical NES class recognized by exportin Msn5. [PDF]

Nat Commun
Fung HYJ, Mittal SR, Niesman AB, Jiou J, Shakya B, Yoshizawa T, Cansizoglu AE, Rout MP, Chook YM.   +8 more
europepmc   +1 more source

Integrative mapping reveals molecular features underlying the mechanism of nucleocytoplasmic transport. [PDF]

Proc Natl Acad Sci U S A
Raveh B, Eliasian R, Rashkovits S, Russel D, Hayama R, Sparks S, Singh D, Lim RYH, Villa E, Rout MP, Cowburn D, Sali A.   +11 more
europepmc   +1 more source

Nap1 and Kap114 co-chaperone H2A-H2B and facilitate targeted histone release in the nucleus. [PDF]

J Cell Biol
Fung HYJ, Jiou J, Niesman AB, Bernardes NE, Chook YM.   +4 more
europepmc   +1 more source

Nuclear β-catenin: molecular regulation, challenges and therapeutic opportunities. [PDF]

Cell Commun Signal
Xie B, Cao Y, Li W, Chen R, Zhou Q, Xie X.   +5 more
europepmc   +1 more source

Small molecule JRMS modulating importin-β1 chaperone activity as a therapeutic strategy reducing TDP-43 pathology. [PDF]

Neurotherapeutics
Shenouda M, Shenouda S, Kartono B, Eid S, Cheng C, Robertson J.   +5 more
europepmc   +1 more source